6/26/2024 Innovations and Advances in RSV Vaccines and Immunobiologics
RSV prevention strategies should focus at this time on protection of the child.
The combined strategies, vaccination of pregnant women against RSV and recommendation of niservimab for infants, were recommended by most members. It is recommended to list a group of clinical conditions for infants to receive niservimab. For example: premature infants (extending the gestational age that has been used in the palivizumab recommendations), other infant health conditions similar to the use of palivizumab (congenital heart disease), Down syndrome and others to be further defined with specialists.
Niservimab could be indicated for children whose mothers have been vaccinated with RSV vaccine in specific situations. For example: mothers vaccinated less than 14 days postpartum.
Evaluate the following points of major concern: cost of immunobiologicals, capacity of the producing laboratory to supply niservimab, low adherence to vaccination by pregnant women.
Regarding operationalization, it was recommended that: niservimab would be recommended throughout the year; concomitant vaccination with other vaccines in the pregnant woman's schedule should be specifically discussed; the gestational period for the RSV vaccine recommendation would be between 32 and 26 weeks.
Influenza Vaccination Strategies (Highly Concentrated Tetravalent Influenza Vaccine - (HD4V) and Adjuvanted Vaccine)
Strategies for new flu vaccines are aimed at protecting the elderly.
At this point, prioritize strategies to improve vaccination coverage of all priority groups, including the elderly.
Evaluate the following points: cost of new vaccines and producer capacity to supply them.
Some specific groups could benefit from highly concentrated and adjuvanted influenza vaccines: over 80 years of age, frail elderly, and people living in long-term care institutions.
Keywords